Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Yale team focuses on blood-brain barrier

The development and maintenance of the blood-brain barrier are dependent on what is called the Wnt signaling pathway, which regulates a number of crucial cellular...

| By Kelley Gipson

Career Newsletter – March 15, 2022

View this email in your browser Career News – March 15, 2022  Artizan Biosciences  Neuroscience Associate Full-time, New Haven Cellifinity Bio  Scientist/Senior Scientist: CAR immune...

| By Kelley Gipson

UConn dental school gets highest-ever funding

The UConn School of Dental Medicine has received its highest-ever level of research funding and retained its number eight research ranking in total direct funding from...

| By Kelley Gipson

Chicago, D.C. flights added to Tweed schedule

Chicago’s Midway and the Raleigh-Durham and Baltimore-Washington international airports will get their own nonstop flights from Tweed New Haven on Avelo Airlines, beginning in May....

| By Kelley Gipson

Weekly Roundup – March 10, 2022

View this email in your browser Weekly Roundup – March 10, 2022  Chesley Chen, Prinicpal in the Life Sciences Practice of CLA, a BioCT member, recently authored a blog...

| By Kelley Gipson

CBIA launches initiative re biotech infrastructure

High demand for biotech lab space in New Haven and across the state has prompted the Connecticut Business & Industry Association (CBIA) to launch an initiative...

| By Kelley Gipson

HBJ publishes its list of ‘2020 Power Players’

The Hartford Business Journal has published its 2022 Power Players, a list that includes 50 private- and public-sector, nonprofit, higher education, real estate and healthcare officials in Greater Hartford who...

| By Kelley Gipson

Career Newsletter – March 8, 2022

View this email in your browser Career News – March 8, 2022  Artizan Biosciences  Neuroscience Associate Full-time, New Haven FreeThink Technologies  Senior Analytical Scientist Full-time, Branford...

| By Kelley Gipson

Trevi sees positive results in chronic cough trial

Trevi Therapeutics reports positive results in its Phase 2 trial of the investigational drug Haduvio in patients with idiopathic pulmonary fibrosis who are suffering from chronic...